CG
ARCT icon

Cutler Group’s Arcturus Therapeutics ARCT Stock Holding History

Cutler Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,200
Closed -$6K – 4874
2022
Q2 		$6K Sell
5,200
-8,900
-63% -$175K ﹤0.01% 3545
2022
Q1 		$21K Sell
14,100
-2,600
-16% -$66.3K ﹤0.01% 2996
2021
Q4 		$98K Buy
16,700
+9,000
+117% +$367K ﹤0.01% 1866
2021
Q3 		$17K Buy
+7,700
New +$345K ﹤0.01% 3476
2021
Q2 		– Sell
-1,600
Closed -$1K – 5628
2021
Q1 		$1K Sell
1,600
-6,700
-81% -$399K ﹤0.01% 5117
2020
Q4 		$18K Buy
8,300
+500
+6% +$33.9K ﹤0.01% 2741
2020
Q3 		$87K Buy
7,800
+4,900
+169% +$243K 0.01% 1412
2020
Q2 		$19K Buy
+2,900
New +$100K ﹤0.01% 2404
2017
Q1 		– Sell
-2,243
Closed -$2K – 6320
2016
Q4 		$2K Sell
2,243
-13,186
-85% -$197K ﹤0.01% 5541
2016
Q3 		$17K Buy
+15,429
New +$498K ﹤0.01% 3574
2016
Q1 		– Sell
-429
Closed -$2K – 6433
2015
Q4 		$2K Buy
+429
New +$19.3K ﹤0.01% 5498

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Cutler Group's ARCT Position: Q1 2023 in Review

Cutler Group sold out of Arcturus Therapeutics (ARCT) in Q1 2023, closing a stake of 600 shares — an estimated $10.8K sold.

Cutler Group first reported a position in ARCT in Q4 2015 and held it in 20 quarters. The position peaked at $455K in Q4 2020. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2023.

  • Cutler Group reported no remaining Arcturus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 600 Arcturus Therapeutics shares in Q1 2023, an estimated $10.8K.
  • Cutler Group first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 20 quarters.
  • Cutler Group's Arcturus Therapeutics position peaked at $455K in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.